<p>Legend Biotech Corporation has announced new long-term clinical and translational data for CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) in the treatment of relapsed/refractory multiple myeloma. Results from the CARTITUDE-1 and CARTITUDE-4 studies indicate that triple-class exposed patients with three prior lines of therapy achieved a median progression-free survival of 50.4 months after a single infusion of CARVYKTI®. Additional data show that 80% of as-treated patients in CARTITUDE-4 with standard-risk cytogenetics remained progression-free and off treatment at 30 months. The company also reported promising first-in-human results from its allogeneic CAR-T candidate LUCAR-G39D in B-cell non-Hodgkin lymphoma. These findings were presented at the American Society of Hematology (ASH) 2025 annual meeting. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Legend Biotech Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-25-007796), on December 08, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here</p>

LEGN

<p>Legend Biotech reports CARVYKTI® achieved a median progression-free survival of 50.4 months in multiple myeloma trials. CARTITUDE-1 and CARTITUDE-4 studies show promising results, with 80% of patients remaining progression-free at 30 months. First-in-human results for LUCAR-G39D in B-cell non-Hodgkin lymphoma were also promising. Findings presented at ASH 2025.</p>

Legend Biotech Reports CARVYKTI® Delivers Median PFS of 50.4 Months in Multiple Myeloma Trial